Sodium-Glucose Cotransporter 2 Inhibitors for Patients With Prostate Cancer Undergoing Hormone Therapy
In this cohort study with a target trial emulation design, SGLT2 inhibitor use was associated with delayed hormone therapy failure in patients with prostate cancer, suggesting a potential oncologic benefit beyond glucose lowering. These findings support the potential of SGLT2 inhibitors in treatment for prostate cancer.
Authors
- Bryan Cho Wing Li
- Chi Yao (ORCID: https://orcid.org/0000-0002-6958-6535)
- Tsun Tsun Stacia Chun (ORCID: https://orcid.org/0009-0009-6715-7815)
- Ruofan Shi (ORCID: https://orcid.org/0009-0005-1001-390X)
- Yongle Zhan
- Rong Na
- Ada Tsui-Lin Ng
- Matthew Kin-Liang Chiu
- Ruochen Ma
- Salida Ali
Institutions
- Chinese University of Hong Kong (HK)
- Shanghai Jiao Tong University (CN)
- Queen Mary Hospital (CN)
- Ruijin Hospital (CN)
- University of Hong Kong (HK)
Publication Details
- Journal
- JAMA Oncology
- Published
- 2026-01-08
- DOI
- https://doi.org/10.1001/jamaoncol.2025.5869
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Impact Fund
- University Grants Committee
- Health and Medical Research Fund